NCT00517257View on ClinicalTrials.gov

Atorvastatin for the Treatment of Retinal Vein Occlusion

PHASE3UnknownINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

August 31, 2007

Study Completion Date

September 30, 2009

Conditions
Retinal Vein OcclusionRetinal Vein ThrombosisCentral Retinal Vein OcclusionBranch Retinal Vein OcclusionThrombosis
Interventions
DRUG

Atorvastatin

80 mg orally once daily for 24 weeks

DRUG

Placebo

Placebo tablet orally once daily for 24 weeks

Trial Locations (1)

M5B 1W8

RECRUITING

St. Michael's Hospital, Toronto

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Unity Health Toronto

OTHER

collaborator

Pfizer

INDUSTRY

collaborator

Canadian Heart Research Centre

OTHER

collaborator

Ontario Association of Optometrists

OTHER

collaborator

Toronto Ophthalmological Society

UNKNOWN

lead

University of Toronto

OTHER

NCT00517257 - Atorvastatin for the Treatment of Retinal Vein Occlusion | Biotech Hunter | Biotech Hunter